Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical …
CL Trimble, MP Morrow, KA Kraynyak, X Shen… - The Lancet, 2015 - thelancet.com
Background Despite preventive vaccines for oncogenic human papillomaviruses (HPVs),
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can …
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can …
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
…, AM Seliga, G Soule, M Morrow, KA Kraynyak… - Science translational …, 2015 - science.org
First identified in 2012, Middle East respiratory syndrome (MERS) is caused by an emerging
human coronavirus, which is distinct from the severe acute respiratory syndrome …
human coronavirus, which is distinct from the severe acute respiratory syndrome …
[HTML][HTML] In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
…, SB Kudchodkar, EL Reuschel, H Choi, KA Kraynyak… - npj Vaccines, 2016 - nature.com
Significant concerns have been raised owing to the rapid global spread of infection and
disease caused by the mosquito-borne Zika virus (ZIKV). Recent studies suggest that ZIKV can …
disease caused by the mosquito-borne Zika virus (ZIKV). Recent studies suggest that ZIKV can …
Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer
C Aggarwal, RB Cohen, MP Morrow, KA Kraynyak… - Clinical Cancer …, 2019 - AACR
Purpose: Clinical responses with programmed death (PD-1) receptor–directed antibodies
occur in about 20% of patients with advanced head and neck squamous cell cancer (HNSCCa)…
occur in about 20% of patients with advanced head and neck squamous cell cancer (HNSCCa)…
Intradermal SynCon® Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers
P Tebas, KA Kraynyak, A Patel… - The Journal of …, 2019 - academic.oup.com
Background Nonlive vaccine approaches that are simple to deliver and stable at room
temperature or 2–8C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. …
temperature or 2–8C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. …
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in …
…, P Tebas, J Agnes, M Giffear, KA Kraynyak… - MedRxiv, 2021 - medrxiv.org
Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global
population has been vaccinated. Here we report the safety and immunogenicity of a DNA …
population has been vaccinated. Here we report the safety and immunogenicity of a DNA …
SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial
KA Kraynyak, E Blackwood, J Agnes… - The Journal of …, 2022 - academic.oup.com
Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
[HTML][HTML] Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL …
RH Vonderheide, KA Kraynyak, AF Shields… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’tumor
associated antigen due to its expression in a vast number of cancers. We …
associated antigen due to its expression in a vast number of cancers. We …
Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy
MP Morrow, KA Kraynyak, AJ Sylvester, M Dallas… - Clinical Cancer …, 2018 - AACR
Purpose: As previously reported, treatment of high-grade cervical dysplasia with VGX-3100
resulted in complete histopathologic regression (CR) concomitant with elimination of HPV16/…
resulted in complete histopathologic regression (CR) concomitant with elimination of HPV16/…
[HTML][HTML] Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
MP Morrow, KA Kraynyak, AJ Sylvester, X Shen… - Molecular Therapy …, 2016 - cell.com
We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA
immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a …
immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a …